Is NeoGenomics (NEO) overvalued or fairly valued?

MarketChacha shows NeoGenomics's valuation in context — a forward P/E of about 38.3, a price-to-book of about 2.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is NeoGenomics's revenue?

NeoGenomics reported revenue of $727.3M for FY2025, with net profit of $-108.0M, per official filings.

What is the share price of NeoGenomics (NEO)?

NeoGenomics last traded at $13.97 (-3.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

NeoGenomics

NEO · NYSE · Healthcare · United States

$13.97-3.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:30 PM

Snapshot

TickerNEO

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees2,500

HeadquartersFort Myers, United States

Market cap$1.8B

P/B2.2

Volume986.52K

Websitewww.neogenomics.com

Filings tracked9

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Profile as reported by Yahoo Finance.

Who owns it

Insiders2.1%
Institutions97.9%
Public & other0.0%

360 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.33%
First Light Asset Management, LLC7.47%
Greenhouse Funds, LLLP6.99%
Vanguard Portfolio Management LLC5.85%
First Trust Advisors LP4.73%
Vanguard Capital Management LLC4.34%
Braidwell LP4.31%
State Street Corporation3.93%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -12.9% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-14.9% → -14.9%

Margin has held broadly steady over the period — stable profitability.

Return on equity-12.9%

Latest ROE of -12.9% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $205.8M · EPS 0.05

Est. earnings growth +81.8%

Next fiscal year

Rev $880.7M · EPS 0.36

Est. earnings growth +102.5%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$4.7252-wk range$15.57

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.8B

Day change

-3.3%

Fwd P/E

38.3

P/B

2.2

Beta

1.74

Revenue (FY2025)

$727.3M

Net margin

-14.9%

ROE

-12.9%

Revenue CAGR (2y)

+10.9%

Net profit (FY2025)

$-108.0M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about NEO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin	ROE
FY2025	$727.3M	$-108.0M	-14.9%	-12.9%
FY2024	$660.6M	$-78.7M	-11.9%	-8.7%
FY2023	$591.6M	$-88.0M	-14.9%	-9.3%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	$186.7M	$-17.1M	-9.2%
2025Q3	$187.8M	$-27.1M	-14.4%
2025Q2	$181.3M	$-45.1M	-24.9%
2025Q1	$168.0M	$-25.9M	-15.4%
2024Q3	$167.8M	$-17.7M	-10.5%
2024Q2	$164.5M	$-18.6M	-11.3%
2024Q1	$156.2M	$-27.1M	-17.3%
2023Q3	$152.0M	$-18.5M	-12.2%
2023Q2	$146.9M	$-24.3M	-16.6%
2023Q1	$137.2M	$-30.8M	-22.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K/A — Reg FD disclosure, Other events, Exhibits
SEC7/22/2026
8-K — Reg FD disclosure, Other events, Exhibits
SEC7/20/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/25/2026material
8-K — Material agreement, Material financial obligation, Unregistered equity sale, Other events, Exhibits
SEC6/22/2026material
8-K — Other events, Exhibits
SEC6/17/2026material
8-K — Other events, Exhibits
SEC6/15/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/22/2026material
8-K — Results of operations, Exhibits
SEC4/28/2026material
10-Q filing
SEC4/28/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.